# SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

> **NCT05900882** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 35 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Bortezomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05900882
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-15
- **Primary completion:** 2025-08-30
- **Final completion:** 2025-08-30
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05900882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05900882, "SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05900882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*